Expression of TGF?1 by Rat Kupffer Cells: Implication for a Pathogenetic Role in Alcoholic Liver Fibrosis

1990 ◽  
Vol 593 (1 Transforming) ◽  
pp. 357-359 ◽  
Author(s):  
MASAKI MATSUOKA ◽  
HIDEKAZU TSUKAMOTO
2017 ◽  
Vol 97 (8) ◽  
pp. 890-902 ◽  
Author(s):  
Tomonori Aoyama ◽  
Kyoko Kuwahara-Arai ◽  
Akira Uchiyama ◽  
Kazuyoshi Kon ◽  
Hironao Okubo ◽  
...  

1991 ◽  
Vol 69 (12) ◽  
pp. 1797-1803 ◽  
Author(s):  
T. C. Peterson ◽  
C. N. Williams ◽  
D. A. Malatjalian

We have previously reported that monocyte aryl hydrocarbon hydroxylase (AHH) activity is depressed in patients with liver disease and is decreased more in cirrhosis than in early stage liver disease. To determine if monocyte AHH activity reflects liver AHH activity, we studied an animal model of cirrhosis, i.e., yellow phosphorus induced cirrhosis in the pig. AHH activity was detectable in monocytes isolated from peripheral blood of normal pigs (0.32 ± 0.13 nmol∙mg−1 P∙h−1, n = 11) and was comparable to the level of AHH activity in hepatic Kupffer cells isolated from wedge or needle biopsies of livers of normal pigs (0.38 ± 0.21, n = 7). The AHH level in pig Kupffer cells was approximately 10% of the AHH level in hepatocytes and microsomes. To induce liver disease, pigs were administered yellow phosphorus (0.6 mg/kg) 5 days per week for 16 weeks. At 4 weeks of treatment, monocyte AHH activity was not different from control and liver histology was normal. Depression of monocyte AHH activity was evident at 8 weeks of treatment when liver fibrosis was seen histologically. At 12 weeks of treatment when histology revealed extensive liver fibrosis and collagen levels were elevated, the level of monocyte AHH activity was decreased 67% compared with controls. Similar changes were observed at 12 weeks in Kupffer cell AHH activity (86% decrease) and hepatocyte AHH activity (70% decrease) compared with controls. These results suggest that monocyte AHH activity reflects liver AHH activity and may be a good indicator of change in liver enzyme function in liver disease in the pig model of cirrhosis.Key words: aryl hydrocarbon hydroxylase, animal model of liver disease, monocyte, hepatocyte, Kupffer cells.


2019 ◽  
Vol 53 (1) ◽  
Author(s):  
Hao Wu ◽  
Guoyong Chen ◽  
Jingyuan Wang ◽  
Minghua Deng ◽  
Fangchao Yuan ◽  
...  

2021 ◽  
Author(s):  
Yuan Nie ◽  
Chen-kai Huang ◽  
Cong Liu ◽  
Xuan Zhu

Abstract Background: Previous studies have indicated that Kupffer cells (KCs) are the main regulatory cells for the activation of hepatic stellate cells (HSCs), and caspase-11/NLRP3 inflammasome signaling plays crucial roles in the activation of monocyte-macrophages. Ursolic acid (UA) is a traditional Chinese medicine with antifibrotic effects, but the molecular mechanism underlying these effects is still unclear.Methods: A mouse primary Kupffer cell line in vitro and liver fibrosis mice (including specific gene knockout mice) in vivo were selected as experimental objects. RT-qPCR and Western blotting techniques were utilized to assess the mRNA and protein expression in each group. ELISA and histological analysis were utilized to assess liver injury and collagen deposition.Results: In vitro, caspase-11/NLRP3 inflammasome signaling promoted the activation of Kupffer cells, and UA inhibited the activation of Kupffer cells by caspase-11/NLRP3 inflammasome signaling. In vivo, UA reversed liver damage and fibrosis in fibrotic mice and was related to Kupffer cells; the expression of Caspase-11/NLRP3 inflammasome signaling in Kupffer cells of the UA group was inhibited. Even in the CCl4 group, the liver damage and fibrosis of NLRP3 knockout mice were alleviated, and related experiments also proved that the inhibitory effect of UA on Kupffer cells was related to the activation of the NLRP3 inflammasome.Conclusion: Caspase-11/NLRP3 inflammasome signal transduction is closely related to the activation of Kupffer cells and the occurrence of liver fibrosis. Additionally, caspase-11/NLRP3 inflammasome signaling serves as a new target for UA antifibrosis treatment.


2003 ◽  
Vol 17 (12) ◽  
pp. 1745-1747 ◽  
Author(s):  
Esther Titos ◽  
Joan Clària ◽  
Anna Planagumà ◽  
Marta López-Parra ◽  
Neus Villamor ◽  
...  

2022 ◽  
Author(s):  
Keqin Ji ◽  
Mingrui Fan ◽  
Dong Huang ◽  
Lingna Sun ◽  
Bingqin Li ◽  
...  

CLD/NIN@LIEV decreases the nonspecific phagocytosis of nanoparticles and suppresses the inflammatory cytokines secreted by Kupffer cells, thus enhancing the therapeutic effects against liver fibrosis.


Sign in / Sign up

Export Citation Format

Share Document